The Latest Cardiac and Vascular News
Timely Home-Based Treatment Creates Pathway to Reduce the National 25% Average for Hospital Re-Admissions Down to Just 6.8% SPOKANE, Wash. and DENVER, Jan. 12, 2023 /PRNewswire/ — Known for a solid commitment to advancing heart and vascular medicine in the Pacific Northwest, MultiCare’s Pulse Heart Institute set out to change the narrative for congestive heart failure patients […]
GENT, Belgium–(BUSINESS WIRE)–FEops announces Euan S. Thomson, PhD has been appointed as new Chairman. Euan Thomson succeeds veteran medical device executive Rob Michiels, who continues to support FEops as an independent board member. FEops has made significant progress with rollout of their HEARTguide structural heart planning software based on digital twin […]
Research collaboration to target severe form of genetic dilated cardiomyopathy Collaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac therapy Collaboration allows Phlox Therapeutics to leverage Solid Biosciences’ vector biology and manufacturing capacities to deliver its RNA therapies to the heart CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. […]
GENEVA, Jan. 10, 2023 /PRNewswire/ — SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions. This comes less than eight months after the company received its first IDE approval for SELUTION SLR in the treatment […]
Newly Assigned Rates Further Validate Commercial Value of the HART Tests KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc., The AI-Powered Cardiac Blood Test Company, today announced the Centers for Medicare & Medicaid Services (CMS) has set a National Medicare payment rate of $390.75 for each of the Company’s three lead proprietary HART® cardiac blood tests. […]
RP-A601 for Arrhythmogenic Cardiomyopathy due to PKP2 pathogenic variants (PKP2-ACM) represents meaningful commercial opportunity with estimated prevalence of 50,000 adults and children in the U.S. and EU; IND filing anticipated in Q2 2023 In support of Phase 2 pivotal study, latest positive Phase 1 data in Danon Disease recently shared […]
Masimo SpHb on the Handheld Masimo Rad-67® Demonstrated “Acceptable Accuracy and Excellent Correlation” with Laboratory Hemoglobin NEUCHATEL, Switzerland–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) today announced the results of a prospective study published in the American Journal of Emergency Medicine in which Dr. Zohair Ahmed Ali Al Aseri and colleagues at King Saud University Medical City and […]
Phase 2 trials underway with ninerafaxstat in three cardiovascular indications; multiple data read-outs expected in 2023 BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced the enrollment of the first patient in Part 2 […]
Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 Anticipated in Second Half 2023 TN-401 IND Submission Planned in Second Half 2023 Cash Runway Extended into First Half 2025 SOUTH SAN […]
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for […]
